Skip to main content
TipRanks
Go Ultimate75% OFF

Ascelia Pharma AB (ACE) AI Stock Analysis

3 Followers
SE:ACE

Ascelia Pharma AB

(Nasdaq OMX AB:ACE)

Select Model
Rating:29Underperform
Price Target:SEK 0.48â–¼(-16.90% Downside)
Action:reiterated
Date:11/13/26

The score is driven primarily by very weak financial fundamentals: zero revenue, a TTM net loss of about SEK 54.7 million, and roughly SEK 61.7 million of annual operating cash burn against an equity base of only about SEK 80 million, pointing to a near-term funding need and likely shareholder dilution. Technicals compound the concern, with the price trading well below all key moving averages — notably the 200-day at 1.865 versus a last close of 0.533 — and negative MACD confirming a prolonged downtrend. Valuation provides no cushion given negative earnings and no dividend. Mitigating factors are a nearly debt-free balance sheet, equity funding close to 88% of assets, and a meaningfully reduced cost base, with losses and burn roughly halved from 2022–2023 peaks. The investment case rests almost entirely on future clinical and partnering milestones rather than current financial performance.

Positive Factors
Low leverageVery low debt reduces refinancing pressure and interest burden while preserving financial flexibility. Compared with a highly leveraged biotech, Ascelia has less obligation to divert future capital toward debt service, leaving more capacity for clinical development and regulatory work if financing remains available.
Negative Factors
No established revenueAscelia has not yet demonstrated commercial demand or revenue scale, leaving its business model dependent on successful development and approval of Orviglance. Until product sales begin, fixed research and operating costs cannot be absorbed by recurring revenue, keeping execution risk elevated.

Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)

-100%-80%-60%-40%-20%0%20%40%SE:ACE-79.50%EWD+17.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 76.65M
Dividend Yield
―
Average Volume (3M)
955.66K
Price to Earnings (P/E)
-1.3
Beta (1Y)
0.67
Revenue Growth
―
EPS Growth
50.59%
Country
Sweden
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ascelia Pharma AB Business Overview & Revenue Model

Company Description

Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trial...

How the Company Makes Money

Ascelia Pharma’s business model is centered on successfully developing, obtaining regulatory approval for, and then commercializing its product candidates, with future revenues expected to come primarily from product sales of its lead candidate, Orvi...

Ascelia Pharma AB Financial Statement Overview

Summary

Ascelia Pharma is a pre-revenue clinical-stage biotech with no sales in any reported period and persistent losses (TTM operating loss of roughly SEK 55.5 million and net loss of about SEK 54.7 million). Operations consumed about SEK 61.7 million of cash over the TTM period, with free cash flow essentially matching the net loss, implying limited runway against an equity base of roughly SEK 80 million and a high likelihood of dilutive financing. The positives are genuine but secondary: losses and cash burn have roughly halved from 2022–2023 levels after pipeline reprioritization, debt is negligible at about SEK 0.3 million, and equity funds close to 88% of assets. However, the capital base has eroded sharply from about SEK 308 million in 2021, and return on equity remains deeply negative at around -62%, leaving financial quality weak on an absolute basis.

Income Statement

11Very Negative

Balance Sheet

45Neutral

Cash Flow

13Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit0-888.00K-938.00K-1.05M-3.89M-8.72M
EBITDA-55.60M-73.24M-66.83M-108.56M-132.06M-128.42M
Net Income-54.75M-76.25M-80.03M-109.29M-131.22M-125.90M
Balance Sheet
Total Assets90.27M111.94M140.92M87.07M218.57M333.49M
Cash, Cash Equivalents and Short-Term Investments27.80M49.86M75.26M21.86M149.56M261.60M
Total Debt285.00K1.04M25.40M1.06M484.00K1.66M
Total Liabilities10.58M12.47M61.98M12.74M37.71M25.66M
Stockholders Equity79.69M99.47M78.94M74.33M180.86M307.83M
Cash Flow
Free Cash Flow-61.66M-72.31M-62.84M-126.79M-125.33M-116.60M
Operating Cash Flow-61.66M-72.25M-62.84M-126.79M-125.26M-116.56M
Investing Cash Flow0-57.00K046.00K-65.00K-38.00K
Financing Cash Flow17.29M48.21M115.19M-936.00K-1,100184.87M

Ascelia Pharma AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.57

Price Trends

50DMA0.62Negative
100DMA0.65Negative
200DMA1.82Negative

Market Momentum

MACD-0.01Negative
RSI50.05Neutral
STOCH30.01Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Neutral. The current price of 0.57 is above the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.62, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 30.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACE.

Ascelia Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ACE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 369.63M1.9363.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BINVSE:BINV49NeutralSEK 193.46M-0.40-128.54%―-83.67%-50.29%
SE:IMMUSE:IMMU48NeutralSEK 240.41M-2.12-19.14%――13.06%
SE:ONCOSE:ONCO44NeutralSEK 747.11M-2.75――65.37%43.28%
SE:ONCOZSE:ONCOZ39UnderperformSEK 84.18M-1.30-970.69%―115.26%-230.43%
SE:ACESE:ACE29UnderperformSEK 76.65M-1.33-62.23%――50.59%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:ACESE:BINVSE:ONCOSE:ONCOZSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ACE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ACEAscelia Pharma AB0.57-2.32-80.17%
SE:BINVBioInvent International AB2.94-27.96-90.49%
SE:ONCOOncopeptides AB1.73-3.24-65.16%
SE:ONCOZOncoZenge AB3.05-1.65-35.06%
SE:IMMUImmunicum AB3.79-1.81-32.32%
SE:CANTACantargia AB1.31-1.92-59.41%

Ascelia Pharma AB Corporate Events

Ascelia Pharma Resolves to Convert Series C Shares for Incentive Program

Nov 9, 2026

Ascelia Pharma’s board resolved on 9 November 2026 to convert 79,142 series C shares into ordinary shares and allot them to participants in its LTI 2023 performance-based share saving program. Eight participants were allotted shares, including 34,410...

FDA Seeks Additional Evidence for Ascelia’s Orviglance

Nov 5, 2026

In July, the U.S. Food and Drug Administration issued a Complete Response Letter for Orviglance, citing issues with clinical data and product documentation. Official minutes from a September Type A meeting confirmed that additional clinical evidence...

Ascelia Pharma Charts New Path for Orviglance After FDA Meeting

Oct 11, 2026

Ascelia Pharma has received official minutes from its Type A meeting with the U.S. FDA regarding the Complete Response Letter for the Orviglance New Drug Application, confirming that the agency still wants additional clinical evidence, ideally from a...

Ascelia Pharma’s Orviglance Study Published in Leading MRI Journal

Sep 24, 2026

Ascelia Pharma AB, a Malmö-based biotech company listed on Nasdaq Stockholm and focused on orphan oncology treatments, is developing two key drug candidates: Orviglance, a manganese-based MRI contrast agent for liver imaging, and Oncoral. The company...

Ascelia Pharma Holds FDA Type A Meeting on Orviglance NDA

Sep 10, 2026

Ascelia Pharma has completed a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued for the Orviglance New Drug Application. The meeting was aimed at clarifying the steps required to secure U.S. reg...

Ascelia Pharma Tightens Costs After FDA Setback on Orviglance

Aug 20, 2026

Ascelia Pharma reported that its primary focus in the first half of 2026 has been advancing Orviglance through the U.S. regulatory process and preparing for potential commercial partnering once approval is secured. The company completed a SEK 20 mill...

Ascelia Pharma Secures FDA Type A Meeting on Orviglance NDA

Aug 17, 2026

Ascelia Pharma said the U.S. Food and Drug Administration has scheduled a Type A meeting on September 9, 2026 to discuss the Complete Response Letter issued for the New Drug Application of Orviglance. The meeting will allow the company and the regula...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026